Notice: This company has been marked as potentially delisted and may not be actively trading. Deciphera Pharmaceuticals (DCPH) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell ...August 16, 2024 | businesswire.comFisher Asset Management LLC Purchases Shares of 62,372 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Fisher Asset Management LLC purchased a new stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 62,372 shares of the company's stock, valued at approximately $1,006,000. FisherJune 23, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Purchased by Goldman Sachs Group Inc.Goldman Sachs Group Inc. raised its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,307,475 shares of the company's stJune 22, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC reduced its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 561,025 shares of the coJune 13, 2024 | marketbeat.comBraidwell LP Has $18.86 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Braidwell LP cut its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 64.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,169,490 shares of the company's stock after selling 2,166,731 shares duriJune 12, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Nebula Research & Development LLCNebula Research & Development LLC boosted its position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 93.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,159 shares of theJune 11, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $25.59Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.59June 10, 2024 | marketbeat.comNew Leaf Venture Partners L.L.C. Sells 632,596 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)New Leaf Venture Partners L.L.C. reduced its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 576,975 shares of the company's stock aJune 8, 2024 | marketbeat.com50,735 Shares in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Acquired by Campbell & CO Investment Adviser LLCCampbell & CO Investment Adviser LLC bought a new position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 50,735 shares of the company's stock, valued at approximately $818,000. Campbell & CO InJune 7, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Armistice Capital LLCArmistice Capital LLC raised its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,200,000 shares of the company's stock after acJune 5, 2024 | marketbeat.comDimensional Fund Advisors LP Raises Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Dimensional Fund Advisors LP raised its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,561,654 shaJune 4, 2024 | marketbeat.comDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetJune 3, 2024 | businesswire.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.55Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $25.55May 31, 2024 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)BNP Paribas Financial Markets boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,653 shares of thMay 28, 2024 | marketbeat.comTrexquant Investment LP Takes $2.19 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,994 shares of the company's stock,May 26, 2024 | marketbeat.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Recommendation of "Hold" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have gMay 24, 2024 | marketbeat.comDeciphera Pharmaceuticals ticks higher as HSR waiting period for ONO sale expiresMay 22, 2024 | msn.comJump Financial LLC Takes $522,000 Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Jump Financial LLC purchased a new position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,375 shares of the company's stoMay 22, 2024 | marketbeat.comPanagora Asset Management Inc. Acquires 144,097 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Panagora Asset Management Inc. grew its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 157.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,845 shares of the company'sMay 19, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)May 16, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock SalesMay 14, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Strong Trading VolumeDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeMay 13, 2024 | marketbeat.comDCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 10, 2024 | investorplace.comFisher Asset Management LLC Acquires New Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,372 shares of the company's stock, vMay 10, 2024 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNKMay 2, 2024 | stockhouse.comDECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPHMay 1, 2024 | businesswire.comBarclays Upgrades Deciphera Pharmaceuticals (DCPH)May 1, 2024 | msn.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Cut to Market Perform at Leerink PartnrsLeerink Partnrs cut Deciphera Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday.May 1, 2024 | marketbeat.comJefferies Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | msn.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Down 5.1% in AprilDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,750,000 shares, a drop of 5.1% from the March 31st total of 6,060,000 shares. Approximately 11.5% of the company's shares are sold short. Based on an average daily trading volume, of 525,500 shares, the days-to-cover ratio is presently 10.9 days.April 30, 2024 | marketbeat.comDeep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)April 30, 2024 | markets.businessinsider.comJonesTrading Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | msn.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume IncreaseDeciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading VolumeApril 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Earns "Neutral" Rating from GuggenheimGuggenheim reiterated a "neutral" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday.April 30, 2024 | marketbeat.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Rating Increased to Equal Weight at BarclaysBarclays raised shares of Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $9.00 to $26.00 in a research report on Tuesday.April 30, 2024 | marketbeat.comONO Enters into a Definitive Agreement to Acquire Deciphera PharmaceuticalsApril 30, 2024 | finance.yahoo.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 30, 2024 | reuters.comINVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPHApril 29, 2024 | prnewswire.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a bApril 29, 2024 | marketbeat.comDeciphera to be acquired by Japanese drug firm for $2.4 billionApril 29, 2024 | msn.comUpdate: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion DealApril 29, 2024 | finance.yahoo.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%April 29, 2024 | finance.yahoo.comJefferies Financial Group Reaffirms Hold Rating for Deciphera Pharmaceuticals (NASDAQ:DCPH)Jefferies Financial Group restated a "hold" rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday.April 29, 2024 | marketbeat.comWhy Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?April 29, 2024 | investorplace.comShareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.April 29, 2024 | prnewswire.comDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $25.03Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $25.03April 29, 2024 | marketbeat.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%April 29, 2024 | barrons.comDCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to ShareholdersApril 29, 2024 | businesswire.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionApril 29, 2024 | reuters.comDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 29, 2024 | businesswire.com Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here DCPH Media Mentions By Week DCPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DCPH News Sentiment▼0.000.41▲Average Medical News Sentiment DCPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DCPH Articles This Week▼02▲DCPH Articles Average Week Get Deciphera Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGIO News Today SNDX News Today XNCR News Today MCRB News Today ROIV News Today RVMD News Today LEGN News Today ITCI News Today VKTX News Today LNTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DCPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
